Abstract
Background: Opicapone (OPC), a once-daily catechol-O-methyltransferase inhibitor, was shown to be effective for end-of-dose motor-fluctuations in Parkinson's disease (PD) patients. We evaluated the efficacy and safety of OPC as first-line adjunctive therapy in levodopa/dopa decarboxylase inhibitors-treated PD patients with end-of-dose motor fluctuations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
